LFG
OCUL icon

Larson Financial Group’s Ocular Therapeutix OCUL Stock Holding History

Larson Financial Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$440 Sell
52
-14
-21% -$133 ﹤0.01% 3335
2025
Q4 		$801 Buy
66
+57
+633% +$692 ﹤0.01% 3016
2025
Q3 		$105 Buy
9
+1
+13% +$12 ﹤0.01% 3326
2025
Q2 		$74 Buy
+8
New +$63 ﹤0.01% 3197

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Larson Financial Group's OCUL Position: Q1 2026 in Review

Larson Financial Group reduced its Ocular Therapeutix (OCUL) stake by 21% in Q1 2026, selling an estimated $133 and leaving 52 shares worth $440. The position accounts for ﹤0.01% of the portfolio, ranked #3335.

Larson Financial Group first reported a position in OCUL in Q2 2025 and has held it in 4 quarters since. The position peaked at $801 in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Larson Financial Group held 52 shares of Ocular Therapeutix worth $440 as of Q1 2026.
  • Larson Financial Group sold 14 Ocular Therapeutix shares in Q1 2026, an estimated $133.
  • Ocular Therapeutix made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3335 holding.
  • Larson Financial Group first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Ocular Therapeutix position peaked at $801 in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.